Fabrikstrasse 2, 4056 Basel
Location: Basel
Discipline: Pharmacology

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.


Pharmacology - Health - Sep 17
Phase III PREVENT study met 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA). All secondary endpoints were also met -   Novartis has submitted to EMA for approval in nr-axSpA, which would be the fourth indication for Cosentyx.
Pharmacology - Health - Sep 13

Both ASCLEPIOS I and II studies met their primary endpoints in patients with relapsing forms of MS (RMS) ; overall ofatumumab (OMB157), a subcutaneous, potent, fully-human antibody targeting CD20 positive B-cells, delivered efficacy with a favorable safety profile -   RMS patients on ofatumumab had a reduction in annualized relapse rate (ARR) by 50.5%  (0.11 vs.

Pharmacology - Life Sciences - Sep 12

New post hoc statistical analysis of the pivotal EXPAND study at ECTRIMS shows that Mayzent (siponimod) can help patients keep their mobility for over four years longer on average * -   Further EXPAND analyses demonstrate Mayzent also significantly reduced grey matter volume loss at one and two y

Pharmacology - Health - Sep 9

The 5-year open-label treatment period (OLTP) examines sustained efficacy and long-term safety of Aimovig (erenumab) in patients with episodic migraine, starting on 70mg and switched after two years to 140mg -   4.5-year data show 77% of the patients who continued on treatment experienced

Pharmacology - Health - Sep 3

Worldwide agreement with Polpharma gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis (RRMS) RRMS affects ~85% of MS patients and can create a substantial social and economic burden on patients, their families and healthcare systems

Pharmacology - Life Sciences - Sep 13

Monitoring disease activity and treatment effectiveness in MS patients in real-time is a serious challenge for physicians -   New data show how the use of two central nervous system-derived proteins in blood as real-time biomarkers for MS could support MS treatment management[1,2] -   New FREEDOM

Pharmacology - Health - Sep 10

Novartis will present 34 abstracts from leading MS portfolio, including the highly anticipated results from the Phase III trial of investigational B-cell therapy ofatumumab (OMB157), data for Mayzent (siponimod) and Gilenya (fingolimod) -   Results from head-to-head Phase III ASCLEPIOS studies ev

Pharmacology - Health - Sep 6

Currently, there are no targeted therapies approved to treat MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), a particularly aggressive form of the disease - Breakthrough Therapy Designation (BTD) now covers treatment-naïve and patients previously treated with platinum-based chemot

Pharmacology - Health - Sep 2

Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one year in heart failure with reduced ejection fraction (HFrEF) patients ; EVALUATE-HF results complement findings -   PROVE-HF establishes significant correlation between im

website preview


Medicine and Life Sciences